CVS Health surpasses earnings expectations and raises full-year guidance amid broader healthcare sector pressure.
CVS Health reported Q1 2026 adjusted earnings per share of $2.57, exceeding both Morgan Stanley’s $2.17 estimate and the $2.18 consensus. The beat extends to its medical benefit ratio, which came in below expectations, easing investor concerns over managed care margins.
Total revenues rose 6.2% year over year to $100.4 billion, while full-year adjusted EPS guidance was lifted to a range of $7.30 to $7.50 from $7.00 to $7.20. Cash flow from operations guidance was also raised to at least $9.5 billion from $9.0 billion.
The results contrast with broader weakness in healthcare stocks, driven by rising medical costs and Medicaid pressures. Analysts noted the print could support further gains in CVS shares.